As shown by evidence, the anti-cancer effects possessed by T cells can be significantly improved by adding inhibitors against LAG3, TIM3 and PD-L1, or which can positively restore responses of HCC-derived T cells to tumor antigens [128]. The gene discussed is CD274; the disease is cancer.